Randomized phase II study of concurrent gefitinib and chemotherapy versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell …

S Oizumi, S Sugawara, K Minato, T Harada, A Inoue… - 2014 - ascopubs.org
8016 Background: The first-line combination of an epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor (TKI) plus platinum-based doublet chemotherapy has yet to be …
被引用次数：7 相关文章

[引用][C] Randomized phase II study of concurrent gefitinib and chemotherapy versus sequential alternating gefitinib and chemotherapy in previously untreated non …

S Oizumi, S Sugawara, K Minato, T Harada… - Journal of Clinical …, 2014 - cir.nii.ac.jp
Randomized phase II study of concurrent gefitinib and chemotherapy versus sequential
alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer (NSCLC) …